Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials In this pilot study, we assessed the ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Afamitresgene ...

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma ...

Cancer survivor Catriona Fraser Harris from Pencaitland to run the 2026 London Marathon after limb-saving surgery.

An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...